Extended Access of Momelotinib in Adults With Myelofibrosis
Status:
Enrolling by invitation
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide extended access and assess long-term safety
of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia
vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies
GS-US-352-0101 (NCT01969838), GS-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746),
SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg
and 200 mg tablets) and have not experienced progression of disease. The secondary objective
is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.